- Home
- SUGP vs PHIO Comparison
SUGP vs PHIO Comparison
Compare SUGP & PHIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SUGP
- PHIO
- Stock Information
- Founded
- SUGP 1998
- PHIO 2011
- Country
- SUGP Hong Kong
- PHIO United States
- Employees
- SUGP N/A
- PHIO N/A
- Industry
- SUGP
- PHIO Biotechnology: Pharmaceutical Preparations
- Sector
- SUGP
- PHIO Health Care
- Exchange
- SUGP NYSE
- PHIO Nasdaq
- Market Cap
- SUGP 8.9M
- PHIO 8.6M
- IPO Year
- SUGP 2024
- PHIO N/A
- Fundamental
- Price
- SUGP $0.80
- PHIO $2.96
- Analyst Decision
- SUGP
- PHIO Strong Buy
- Analyst Count
- SUGP 0
- PHIO 2
- Target Price
- SUGP N/A
- PHIO $9.00
- AVG Volume (30 Days)
- SUGP 30.6K
- PHIO 701.6K
- Earning Date
- SUGP 07-21-2025
- PHIO 05-15-2025
- Dividend Yield
- SUGP N/A
- PHIO N/A
- EPS Growth
- SUGP 1.19
- PHIO N/A
- EPS
- SUGP 0.11
- PHIO N/A
- Revenue
- SUGP $23,446,259.00
- PHIO N/A
- Revenue This Year
- SUGP N/A
- PHIO N/A
- Revenue Next Year
- SUGP N/A
- PHIO N/A
- P/E Ratio
- SUGP $7.62
- PHIO N/A
- Revenue Growth
- SUGP 11.29
- PHIO N/A
- 52 Week Low
- SUGP $0.52
- PHIO $0.97
- 52 Week High
- SUGP $3.25
- PHIO $9.79
- Technical
- Relative Strength Index (RSI)
- SUGP 49.03
- PHIO 77.11
- Support Level
- SUGP $0.76
- PHIO $1.71
- Resistance Level
- SUGP $0.86
- PHIO $2.08
- Average True Range (ATR)
- SUGP 0.08
- PHIO 0.18
- MACD
- SUGP -0.02
- PHIO 0.09
- Stochastic Oscillator
- SUGP 14.71
- PHIO 84.46
About SUGP SU GROUP HLDGS LTD
SU Group Holdings Ltd and its subsidiaries is an integrated security-related services company. The company has two reportable segments: security-related engineering services, and security guarding and screening services and related vocational training services. The company generates the majority of its revenue from the security-related engineering services segment. Geographically operates in Hong Kong, and Other foreign countries, with maximum revenue from Kong Kong.
About PHIO Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.